In the latest session, Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) closed at $40.05 down -6.16% from its previous closing price of $42.68. In other words, the price has decreased by -$2.63 from its previous closing price. On the day, 639050 shares were traded. RYTM stock price reached its highest trading level at $42.07 during the session, while it also had its lowest trading level at $39.85.
Ratios:
For a deeper understanding of Rhythm Pharmaceuticals Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.43 and its Current Ratio is at 5.58. In the meantime, Its Debt-to-Equity ratio is 0.63 whereas as Long-Term Debt/Eq ratio is at 0.63.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Morgan Stanley on December 19, 2023, Upgraded its rating to Overweight and sets its target price to $55 from $29 previously.
On August 01, 2023, BofA Securities Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $22 to $27.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 21 ’24 when Shulman Joseph sold 18,235 shares for $40.34 per share. The transaction valued at 735,600 led to the insider holds 30 shares of the business.
Lee Jennifer Kayden sold 18,235 shares of RYTM for $707,005 on Mar 20 ’24. The EVP, Head of North America now owns 6,852 shares after completing the transaction at $38.77 per share. On Mar 19 ’24, another insider, Meeker David P, who serves as the President and CEO of the company, sold 45,494 shares for $39.22 each. As a result, the insider received 1,784,275 and left with 174,605 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RYTM now has a Market Capitalization of 2.41B and an Enterprise Value of 2.13B. For the stock, the TTM Price-to-Sale (P/S) ratio is 31.11 while its Price-to-Book (P/B) ratio in mrq is 14.02. Its current Enterprise Value per Revenue stands at 27.52 whereas that against EBITDA is -12.65.
Stock Price History:
Over the past 52 weeks, RYTM has reached a high of $52.57, while it has fallen to a 52-week low of $15.50. The 50-Day Moving Average of the stock is 44.08, while the 200-Day Moving Average is calculated to be 31.74.
Shares Statistics:
For the past three months, RYTM has traded an average of 663.29K shares per day and 622.2k over the past ten days. A total of 59.43M shares are outstanding, with a floating share count of 53.14M. Insiders hold about 11.63% of the company’s shares, while institutions hold 102.59% stake in the company. Shares short for RYTM as of Mar 15, 2024 were 9.2M with a Short Ratio of 13.87, compared to 8.76M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 15.29% and a Short% of Float of 24.55%.
Earnings Estimates
There are 9 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$2.15 for the current quarter, with a high estimate of -$0.59 and a low estimate of -$2.4, while EPS last year was -$0.92. The consensus estimate for the next quarter is -$0.66, with high estimates of -$0.59 and low estimates of -$0.76.
Analysts are recommending an EPS of between -$2.19 and -$4.95 for the fiscal current year, implying an average EPS of -$4.11. EPS for the following year is -$2.01, with 9 analysts recommending between -$0.66 and -$3.84.
Revenue Estimates
A total of 8 analysts believe the company’s revenue will be $27.69M this quarter.It ranges from a high estimate of $31.5M to a low estimate of $25.8M. As of the current estimate, Rhythm Pharmaceuticals Inc.’s year-ago sales were $11.47M, an estimated increase of 141.40% from the year-ago figure. For the next quarter, 8 analysts are estimating revenue of $32.28M, an increase of 67.90% less than the figure of $141.40% in the same quarter last year. There is a high estimate of $34.56M for the next quarter, whereas the lowest estimate is $29.6M.
A total of 9 analysts have provided revenue estimates for RYTM’s current fiscal year. The highest revenue estimate was $149.12M, while the lowest revenue estimate was $115.61M, resulting in an average revenue estimate of $134.95M. In the same quarter a year ago, actual revenue was $77.43M, up 74.30% from the average estimate. Based on 9 analysts’ estimates, the company’s revenue will be $208.59M in the next fiscal year. The high estimate is $307.95M and the low estimate is $164.72M. The average revenue growth estimate for next year is up 54.60% from the average revenue estimate for this year.
